Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTHNASDAQ:FNCHNYSE:JATTNASDAQ:ONCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTHCyclo Therapeutics$0.72$0.72$0.55▼$1.45$23.72M-0.57532,857 shsN/AFNCHFinch Therapeutics Group$13.20+1.5%$13.17$1.10▼$15.85$21.20M1.262,174 shs4,899 shsJATTJATT Acquisition$1.18-2.5%$1.21$7.80▼$12.38$20.36MN/A41,322 shs171,748 shsONCESpark Therapeutics$0.18$113.43$34.53▼$114.20$6.94M2.05891,560 shsN/A10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTHCyclo Therapeutics0.00%0.00%0.00%0.00%-40.93%FNCHFinch Therapeutics Group+1.54%-1.73%-3.65%-6.10%+877.78%JATTJATT Acquisition-2.48%+6.31%+15.69%-12.92%-65.09%ONCESpark Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTHCyclo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFNCHFinch Therapeutics Group0.3392 of 5 stars0.03.00.00.00.01.70.6JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AONCESpark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTHCyclo Therapeutics 2.33Hold$0.9531.83% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/AJATTJATT Acquisition 0.00N/AN/AN/AONCESpark Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTHCyclo Therapeutics$870.73K27.24N/AN/A$0.21 per share3.43FNCHFinch Therapeutics Group$110K192.72N/AN/A$14.25 per share0.93JATTJATT AcquisitionN/AN/A$0.04 per share27.08($0.53) per shareN/AONCESpark Therapeutics$64.72M0.11N/AN/A$13.15 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTHCyclo Therapeutics-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/AFNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AJATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AONCESpark Therapeutics-$78.82M-$2.11N/AN/AN/A-358.41%-59.10%-33.13%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTHCyclo TherapeuticsN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AONCESpark TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTHCyclo TherapeuticsN/A0.170.16FNCHFinch Therapeutics GroupN/A3.873.87JATTJATT AcquisitionN/A0.150.15ONCESpark Therapeutics0.354.674.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTHCyclo Therapeutics68.55%FNCHFinch Therapeutics Group21.77%JATTJATT Acquisition47.97%ONCESpark Therapeutics88.37%Insider OwnershipCompanyInsider OwnershipCYTHCyclo Therapeutics29.78%FNCHFinch Therapeutics Group44.90%JATTJATT Acquisition20.00%ONCESpark Therapeutics6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTHCyclo Therapeutics932.92 million23.12 millionNo DataFNCHFinch Therapeutics Group1901.61 million885,000No DataJATTJATT Acquisition317.25 million13.80 millionNot OptionableONCESpark Therapeutics36838.52 millionN/ANo DataONCE, CYTH, FNCH, and JATT HeadlinesRecent News About These CompaniesSpark layoffs won’t derail Philadelphia’s biotech surge, city official saysMay 10, 2025 | technical.lyTHow Spark's layoffs could affect University City real estateApril 11, 2025 | bizjournals.comDespite Spark's massive layoffs, co-founder Jeff Marrazzo says its legacy will endureApril 9, 2025 | bizjournals.comSpark Therapeutics files notice to lay off 300 employees this yearApril 5, 2025 | technical.lyTSpark Therapeutics Cuts 298 Employees as Part of ReorganizationApril 4, 2025 | biospace.comBSpark Therapeutics is laying off 337 people, more than half its workforce, starting in MayApril 3, 2025 | msn.comDoes the Spark Therapeutics writedown undermine Philly’s biotech swagger?March 18, 2025 | technical.lyTRoche to buy gene therapy firm Spark for $4.8 billionMarch 13, 2025 | pharmaphorum.comPRoche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy UnitMarch 12, 2025 | biospace.comBSpark Therapeutics, a Philly biotech pioneer, is being restructured amid financial write-downsMarch 4, 2025 | msn.comPfizer shelves Beqvez, a Spark Therapeutics developed productFebruary 24, 2025 | bizjournals.comSpark Therapeutics co-founder back at the helm of a Philadelphia gene therapy companyJanuary 14, 2025 | bizjournals.comSpark reassures on safety of haemophilia gene therapyDecember 25, 2024 | pharmaphorum.comPRoche mothballs another hemophilia A gene therapy under Spark amid plans to debut new hematologic assetDecember 17, 2024 | fiercebiotech.comFHow ADHD wired me for scientific discoveryNovember 12, 2024 | statnews.comSHuntington Study Group (HSG) Conference 2024 – Day 1November 11, 2024 | en.hdbuzz.netEBitcoin breaks $81,000 for first time on Trump trades; UK government sells £1bn of NatWest shares – business liveNovember 11, 2024 | msn.comMeet the contenders: Vote for the winners of Philly’s 2024 Technical.ly AwardsNovember 7, 2024 | technical.lyTDenver police investigate deadly hit-and-run at South Sheridan and Evans AvenueNovember 6, 2024 | yahoo.comTrump trades: US dollar, stock futures, bonds, BitcoinNovember 6, 2024 | sharecafe.com.auSNew MarketBeat Followers Over TimeTop HeadlinesView All HeadlinesRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernPalantir Soars on Government Deals as Valuation Debate LingersBy Chris Markoch | June 3, 2025View Palantir Soars on Government Deals as Valuation Debate LingersWant AI Exposure? These 3 ETFs Offer Different AnglesBy Chris Markoch | June 9, 2025View Want AI Exposure? These 3 ETFs Offer Different AnglesMarketBeat Week in Review – 05/26 - 05/30By MarketBeat Staff | May 31, 2025View MarketBeat Week in Review – 05/26 - 05/30ONCE, CYTH, FNCH, and JATT Company DescriptionsCyclo Therapeutics NASDAQ:CYTH$0.72 0.00 (0.00%) As of 03/26/2025Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.Finch Therapeutics Group NASDAQ:FNCH$13.20 +0.20 (+1.54%) As of 06/26/2025 03:41 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.JATT Acquisition NYSE:JATT$1.18 -0.03 (-2.48%) As of 06/25/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Spark Therapeutics NASDAQ:ONCESpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Tesla: The Next Month Could Make or Break the Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
